GO:0034380 high-density lipoprotein particle assembly: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034380 describes the non-covalent aggregation and arrangement of proteins and lipids to form a high-density lipoprotein (HDL) particle.
• HDL assembly is initiated by lipid-poor apolipoprotein A-I (APOA1) and requires the ATP-binding cassette transporter ABCA1 for cellular lipid efflux.
• The process is central to reverse cholesterol transport, the pathway that moves excess cholesterol from peripheral tissues to the liver for excretion.
• Defects in HDL assembly are linked to cardiovascular disease, metabolic disorders, and neurodegenerative conditions such as Alzheimer's disease.
• Key protein players include APOA1, ABCA1, APOA2, APOC1, APOC2, APOC3, APOD, APOE, APOM, LCAT, PLTP, CETP, and SR-B1.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of HDL assembly genes in human cell systems.
Description
High-density lipoprotein (HDL) particles are supramolecular assemblies of proteins and lipids that play a central role in cholesterol transport and cardiovascular health. The biological process by which these particles are formed is annotated as GO:0034380, high-density lipoprotein particle assembly, defined as the non-covalent aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle. This process is essential for reverse cholesterol transport, the pathway that removes excess cholesterol from peripheral tissues and returns it to the liver for excretion. Researchers study HDL assembly to understand lipid metabolism, atherosclerosis, and related metabolic diseases. The assembly process begins with the lipidation of apolipoprotein A-I (APOA1) by the ATP-binding cassette transporter ABCA1, followed by remodeling steps involving enzymes such as LCAT and PLTP. Experimental models, including CRISPR-engineered cell lines and synthetic HDL nanoparticles, have been developed to dissect the molecular mechanisms and therapeutic potential of HDL assembly.
high-density lipoprotein particle assembly At A Glance
| GO ID | GO:0034380 |
|---|---|
| GO term | high-density lipoprotein particle assembly |
| Ontology | biological_process |
| Synonym | HDL assembly |
| Definition | The non-covalent aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle. |
| Major function | Formation of HDL particles for reverse cholesterol transport and lipid homeostasis. |
| Key cellular location | Plasma membrane, extracellular space, and endoplasmic reticulum. |
| Related diseases | Cardiovascular disease, metabolic syndrome, Alzheimer's disease. |
| Experimental models | CRISPR knockout/knock-in cell lines, synthetic HDL nanoparticles, animal models. |
What Is GO:0034380?
GO:0034380, high-density lipoprotein particle assembly, is the biological process in which proteins and lipids non-covalently aggregate and arrange into a high-density lipoprotein particle. This process involves the initial lipidation of apolipoproteins, primarily APOA1, by cellular lipid transporters, followed by the fusion and remodeling of lipid-poor intermediates into mature spherical HDL particles.
Why Is high-density lipoprotein particle assembly Important in Cell Biology?
HDL assembly is critical for maintaining cholesterol homeostasis and protecting against atherosclerosis. The process determines the concentration, size, and functionality of HDL particles, which are inversely correlated with cardiovascular risk. Understanding HDL assembly provides insights into lipid metabolism disorders and offers targets for therapeutic intervention in cardiovascular and neurodegenerative diseases.
• Maintains reverse cholesterol transport, removing excess cholesterol from peripheral tissues.
• Prevents cholesterol accumulation in macrophages, reducing foam cell formation and atherosclerosis.
• Regulates plasma HDL levels, a key biomarker for cardiovascular risk.
• Influences inflammation and immune responses through HDL-associated proteins.
• Plays a role in brain lipid metabolism via astrocytic APOE lipidation.
• Provides a target for synthetic HDL mimetics in cancer therapy.
• Involved in drug delivery and nanoparticle design for cardiovascular research.
• Dysregulation contributes to metabolic syndrome and type 2 diabetes.
• Experimental manipulation of HDL assembly genes can alter disease progression in models.
• Centrifugation artifacts can damage HDL, highlighting the need for careful sample handling.
What Happens During high-density lipoprotein particle assembly?
Initiation by APOA1 and ABCA1
In simple terms: The process starts when a protein called APOA1 grabs lipids from the cell membrane with the help of a transporter called ABCA1.
HDL assembly begins with the synthesis and secretion of lipid-poor apolipoprotein A-I (APOA1) by the liver and intestine. APOA1 interacts with the ATP-binding cassette transporter ABCA1 on the cell surface, which facilitates the efflux of phospholipids and cholesterol to APOA1, forming discoidal pre-beta HDL particles. This step is rate-limiting for HDL biogenesis and is essential for reverse cholesterol transport.
Lipidation and formation of discoidal HDL
In simple terms: APOA1 collects more lipids and changes shape into a flat disc, which is the first form of HDL.
Following initial lipidation, APOA1 undergoes conformational changes that allow it to solubilize additional lipids, forming discoidal HDL particles. These particles are composed of a phospholipid bilayer stabilized by APOA1 molecules arranged in a belt-like structure. The discoidal HDL serves as a substrate for lecithin-cholesterol acyltransferase (LCAT), which esterifies free cholesterol and drives the maturation of HDL.
Maturation by LCAT and PLTP
In simple terms: Enzymes like LCAT and PLTP remodel the disc-shaped HDL into a round, mature particle.
LCAT converts free cholesterol to cholesteryl esters, which move into the core of the particle, transforming discoidal HDL into spherical HDL. Phospholipid transfer protein (PLTP) facilitates the transfer of phospholipids between lipoproteins and contributes to the fusion of HDL particles, generating larger spherical HDL. Cholesteryl ester transfer protein (CETP) can exchange cholesteryl esters from HDL to apoB-containing lipoproteins, influencing HDL composition and function.
Remodeling and reverse cholesterol transport
In simple terms: Mature HDL delivers cholesterol to the liver and other tissues, completing the transport cycle.
Mature spherical HDL particles interact with scavenger receptor class B type I (SR-B1) on hepatocytes and steroidogenic tissues, mediating the selective uptake of cholesteryl esters. This step completes reverse cholesterol transport, allowing cholesterol to be excreted into bile or used for steroid hormone synthesis. HDL particles can also be remodeled by endothelial lipase and hepatic lipase, affecting their size and function.
Alternative assembly pathways in the brain
In simple terms: In the brain, a similar process happens with APOE instead of APOA1 to form HDL-like particles.
In the central nervous system, astrocytes produce APOE, which undergoes lipidation by ABCA1 to form HDL-like particles. This process is isoform-specific and cell-state-dependent, with APOE4 showing altered lipidation compared to APOE3. Brain HDL assembly is critical for cholesterol transport and neuronal function, and its dysfunction is implicated in Alzheimer's disease.
Key Genes Involved in GO:0034380 high-density lipoprotein particle assembly
The following genes and proteins are central to high-density lipoprotein particle assembly, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOA1 | Primary structural apolipoprotein of HDL; initiates assembly | Target for HDL biogenesis studies; knockout reduces HDL |
| ABCA1 | Transporter that lipidates APOA1; rate-limiting for HDL assembly | Mutations cause Tangier disease; knockout abolishes HDL |
| APOA2 | Second most abundant HDL apolipoprotein; modulates HDL metabolism | Affects HDL size and function; knockout models available |
| APOC1 | Inhibits CETP and modulates HDL remodeling | Overexpression alters HDL levels |
| APOC2 | Activator of lipoprotein lipase; affects HDL metabolism | Deficiency causes hypertriglyceridemia |
| APOC3 | Inhibits lipoprotein lipase and hepatic lipase | Associated with hypertriglyceridemia and cardiovascular risk |
| APOD | Lipid-binding protein in HDL; antioxidant properties | Linked to Alzheimer's disease |
| APOE | Key apolipoprotein in brain HDL; isoform-specific lipidation | APOE4 risk factor for Alzheimer's disease |
| APOM | HDL-associated protein; involved in lipid transport | Potential biomarker for cardiovascular disease |
| LCAT | Enzyme that esterifies cholesterol; drives HDL maturation | Deficiency causes fish-eye disease and renal failure |
| PLTP | Transfers phospholipids; remodels HDL | Knockout reduces HDL size |
| CETP | Transfers cholesteryl esters between lipoproteins | Inhibition raises HDL; target for cardiovascular drugs |
| SR-B1 | Receptor for selective HDL cholesteryl ester uptake | Knockout increases HDL cholesterol |
| ABCG1 | Transporter that effluxes cholesterol to HDL | Works with ABCA1 in reverse cholesterol transport |
| LIPC | Hepatic lipase; remodels HDL | Polymorphisms affect HDL levels |
| LIPG | Endothelial lipase; phospholipase that reduces HDL | Inhibition raises HDL |
| SCARB1 | Gene encoding SR-B1; mediates HDL cholesterol uptake | Knockout models show impaired reverse transport |
| NR1H3 | Liver X receptor; regulates ABCA1 and APOE expression | Target for HDL-raising therapies |
How Is high-density lipoprotein particle assembly Regulated?
HDL assembly is regulated at multiple levels. Transcriptional regulation of APOA1, ABCA1, and APOE is controlled by nuclear receptors such as liver X receptor (LXR) and peroxisome proliferator-activated receptor alpha (PPARα). Post-translational modifications of APOA1, including oxidation and glycation, can impair its lipidation and HDL assembly. Cellular cholesterol content and ABCA1 activity are reciprocally regulated; excess cholesterol increases ABCA1 expression and promotes efflux. In the brain, APOE lipidation is regulated by astrocyte activation state and isoform-specific factors. Additionally, plasma factors such as CETP and PLTP modulate HDL remodeling and interconversion.
high-density lipoprotein particle assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCA1 | Tangier disease; near-absent HDL | CRISPR knockout in HepG2 cells; cholesterol efflux assay |
| APOA1 | Low HDL; cardiovascular risk | Knockout and overexpression in Huh7 cells |
| APOE | Alzheimer's disease; impaired brain HDL assembly | CRISPR knock-in of APOE4 in iPSC-derived astrocytes |
| LCAT | Fish-eye disease; renal failure | Point mutation knock-in in HEK293 cells |
| CETP | Altered HDL levels; cardiovascular risk | Overexpression in transgenic models |
Cardiovascular Disease and Atherosclerosis
Impaired HDL assembly leads to low plasma HDL cholesterol and increased risk of atherosclerosis. Mutations in ABCA1 cause Tangier disease, characterized by near-absent HDL and cholesterol accumulation in tissues. CETP deficiency and LCAT deficiency also disrupt HDL assembly and are associated with cardiovascular pathology. Synthetic HDL nanoparticles are being developed to mimic HDL function and treat cardiovascular disease.
Neurodegeneration and Alzheimer's Disease
In the brain, APOE lipidation by ABCA1 is essential for HDL-like particle assembly. The APOE4 isoform exhibits impaired lipidation compared to APOE3, contributing to amyloid-beta accumulation and neurodegeneration. Dysfunctional brain HDL assembly is implicated in Alzheimer's disease pathogenesis, making it a therapeutic target.
Metabolic Disorders and Cancer
HDL assembly defects are linked to metabolic syndrome, type 2 diabetes, and obesity. In cancer, HDL mimetics have been explored for drug delivery and chemoimmunotherapy, as seen in triple-negative breast cancer models. Adenosine-modulating synthetic HDL can enhance antitumor immunity.
From high-density lipoprotein particle assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ABCA1 loss abolish HDL assembly? | ABCA1 knockout in HepG2 or J774 cells |
| Does APOE4 impair astrocytic HDL lipidation? | APOE4 knock-in in iPSC-derived astrocytes |
| Can APOA1 point mutations alter HDL size? | APOA1 point mutation knock-in in Huh7 cells |
| Does LCAT overexpression increase mature HDL? | LCAT overexpression in HEK293 cells |
| Can synthetic HDL nanoparticles mimic HDL function? | Lipid-conjugated core scaffold nanoparticles |
| Does CETP inhibition raise HDL? | CETP knockout or inhibitor treatment in cell models |
How to Study the high-density lipoprotein particle assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cholesterol efflux assay | ABCA1-mediated lipid efflux to APOA1 | Screening for HDL assembly regulators |
| FPLC lipoprotein profiling | HDL particle size and distribution | Characterizing knockout effects |
| Mass spectrometry | Apolipoprotein and lipid composition | Proteomic analysis of HDL |
| CRISPR knockout screen | Genes required for HDL assembly | Discovery of novel regulators |
| Nanoparticle tracking analysis | HDL particle size and concentration | Synthetic HDL characterization |
| Fluorescence microscopy | Cellular lipid efflux and HDL formation | Visualizing assembly in live cells |
| Western blot | APOA1 and ABCA1 protein levels | Validating knockout/overexpression |
| qPCR | mRNA expression of HDL genes | Transcriptional regulation studies |
Lipid and Lipoprotein Profiling
HDL assembly can be assessed by measuring cholesterol efflux, HDL particle size, and apolipoprotein composition using assays such as FPLC, gel electrophoresis, and mass spectrometry. Centrifugation conditions must be carefully controlled to avoid damaging HDL particles.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes required for HDL assembly by selecting for cells with altered cholesterol efflux or HDL binding. These screens have revealed novel regulators of ABCA1 and APOA1.
Imaging and Nanoparticle Tracking
Fluorescence microscopy and nanoparticle tracking analysis can visualize HDL assembly and particle formation in real time. Synthetic HDL nanoparticles with fluorescent labels enable tracking of lipid and protein components.
Proteomics and Lipidomics
Mass spectrometry-based proteomics and lipidomics can quantify apolipoprotein composition and lipid species in HDL particles, providing insights into assembly intermediates.
How CRISPR Can Be Used to Study GO:0034380 high-density lipoprotein particle assembly
Knockout
CRISPR knockout of ABCA1 or APOA1 in hepatic cell lines abolishes HDL assembly, providing a clean background to study the process. Knockout models are essential for identifying rate-limiting steps and compensatory pathways.
Point Mutation
Point mutations in APOA1 or LCAT can be introduced to mimic human disease variants and assess their impact on HDL assembly and function. These models help dissect structure-function relationships.
Knock-in
Knock-in of APOE4 or other disease-associated alleles into iPSC-derived cells allows study of isoform-specific effects on brain HDL assembly. Knock-in models are valuable for neurodegenerative disease research.
Overexpression
Overexpression of LCAT, CETP, or PLTP in cell lines can enhance or alter HDL assembly, enabling gain-of-function studies. Overexpression models are used to test therapeutic targets.
How EDITGENE Supports high-density lipoprotein particle assembly Research
Researchers studying high-density lipoprotein particle assembly-related genes often need to determine whether a candidate gene is causally involved in HDL formation, maturation, or function. CRISPR-based genome editing provides a precise way to manipulate these genes in relevant cell models, enabling mechanistic studies and therapeutic target validation.
Contact EDITGENE today to design your custom CRISPR model for high-density lipoprotein particle assembly research.
Frequently Asked Questions About high-density lipoprotein particle assembly
What is GO:0034380?
GO:0034380 is the Gene Ontology term for high-density lipoprotein particle assembly, the biological process of forming HDL particles from proteins and lipids.
What genes are involved in high-density lipoprotein particle assembly?
Key genes include APOA1, ABCA1, APOA2, APOC1-3, APOD, APOE, APOM, LCAT, PLTP, CETP, and SR-B1.
How is HDL assembly regulated?
HDL assembly is regulated by nuclear receptors (LXR, PPARα), cellular cholesterol levels, and enzymes such as LCAT and PLTP.
What diseases are linked to defective HDL assembly?
Defective HDL assembly is linked to cardiovascular disease, Tangier disease, metabolic syndrome, and Alzheimer's disease.
What is the role of ABCA1 in HDL assembly?
ABCA1 transports lipids to APOA1, forming discoidal HDL; its deficiency causes Tangier disease and near-absent HDL.
How can I study HDL assembly in the lab?
Common methods include cholesterol efflux assays, FPLC, mass spectrometry, and CRISPR knockout screens.
What are synthetic HDL nanoparticles?
Synthetic HDL nanoparticles are engineered particles that mimic HDL structure and function for drug delivery and therapy.
Does APOE play a role in brain HDL assembly?
Yes, APOE is lipidated by ABCA1 in astrocytes to form HDL-like particles; APOE4 shows impaired lipidation.
Can CRISPR be used to study HDL assembly?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise manipulation of HDL assembly genes.
What is reverse cholesterol transport?
Reverse cholesterol transport is the pathway by which HDL removes cholesterol from peripheral tissues and delivers it to the liver.
Conclusion
High-density lipoprotein particle assembly (GO:0034380) is a fundamental biological process that maintains cholesterol homeostasis and protects against cardiovascular and neurodegenerative diseases. Advances in CRISPR genome editing and synthetic HDL technology are accelerating the discovery of new regulators and therapeutic strategies. Continued research into HDL assembly mechanisms will provide insights into lipid metabolism and open new avenues for disease intervention.
References
- 1. Yokoyama S. 2006. Assembly of high-density lipoprotein.. Arterioscler Thromb Vasc Biol 26(1):20-7 PMID: 16284193
- 2. Henrich SE et al.. 2019. Supramolecular Assembly of High-Density Lipoprotein Mimetic Nanoparticles Using Lipid-Conjugated Core Scaffolds.. J Am Chem Soc 141(25):9753-9757 PMID: 31177775
- 3. Gong X et al.. 2024. Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer.. J Control Release 367:637-648 PMID: 38295994
- 4. Lindner K et al.. 2022. Isoform- and cell-state-specific lipidation of ApoE in astrocytes.. Cell Rep 38(9):110435 PMID: 35235798
- 5. Illingworth DR. 1993. Lipoprotein metabolism.. Am J Kidney Dis 22(1):90-7 PMID: 8322800
- 6. Ginsberg HN. 1998. Lipoprotein physiology.. Endocrinol Metab Clin North Am 27(3):503-19 PMID: 9785050
- 7. Kornmueller K et al.. 2019. Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.. Molecules 24(15) PMID: 31382521
- 8. Munroe WH et al.. 2015. Excessive centrifugal fields damage high density lipoprotein.. J Lipid Res 56(6):1172-81 PMID: 25910941
